Top five pharmaceutical companies expected to fare well in second quarter

Published: 2012-07-02 06:59:00

Updated: 2012-07-02 06:59:00

Despite the brunt of government-imposed price cuts and the stepped-up competition, the so-called “big five” drug makers in Korea will see their revenues increase in the second quarter of this year, unlike the original expectation.

Korea’s largest Dong-A Pharmaceutical is projected to post 240....

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK